Status:
UNKNOWN
Study of HLA-DR in Cell Cultures Isolated From Primary Squamous Cell Carcinoma
Lead Sponsor:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Conditions:
Squamous Cell Carcinoma of the Head and Neck
Cancer
Eligibility:
All Genders
Brief Summary
In our previous study (title: Expression of Major Histocompatibility Complex Molecules class II- HLA-DR in Squamous Cell Carcinoma of the Head and Neck. ID 2222)the Authors verified that the epithelia...
Detailed Description
Several studies have demonstrated a correlation between the expression on tumor cells of MHC II (major histocompatibility complex class II) molecules, in particular of HLA-DR (human luekocyte antigen)...
Eligibility Criteria
Inclusion
- diagnosis of primary squamous cell carcinoma of the head and neck, 2) signing of informed consent for study involvement.
Exclusion
- 1\) patients diagnosed with non-primary squamous cell carcinoma of the head and neck and already undergoing radiotherapy, chemotherapy and immunotherapy, biological therapy.
Key Trial Info
Start Date :
March 2 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 2 2024
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT06041464
Start Date
March 2 2021
End Date
March 2 2024
Last Update
September 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fondazione Policlinico Universitario Gemelli, Irccs
Rome, Lazio, Italy, 00168